Members of the state’s opioid advisory board railed at city officials Wednesday over the lack of transparency about how funds designated for treatment, recovery and prevention have been spent.
For years New York has procured naloxone from a single supplier, but Hikma Pharmaceuticals is fighting hard to get a contract — despite evidence that their double-dose version increases the risk of withdrawal symptoms.
Thousands of free harm-reduction and sanitary supplies have been dispensed by the devices, but the Department of Health and Mental Hygiene quietly halted new installations in May.